S&P 500   3,952.19 (+0.46%)
DOW   33,667.62 (+0.21%)
QQQ   282.85 (+0.83%)
AAPL   141.91 (+0.69%)
MSFT   246.30 (+0.79%)
META   115.50 (+1.38%)
GOOGL   94.06 (-0.93%)
AMZN   89.76 (+1.47%)
TSLA   172.33 (-0.98%)
NVDA   168.88 (+4.76%)
NIO   13.31 (+5.80%)
BABA   93.94 (+6.35%)
AMD   69.55 (-0.84%)
T   19.14 (-0.83%)
MU   55.18 (+2.53%)
CGC   3.04 (-6.17%)
F   13.10 (+0.00%)
GE   83.22 (-2.09%)
DIS   92.45 (+0.33%)
AMC   6.13 (+1.32%)
PYPL   74.15 (-0.36%)
PFE   51.72 (+2.95%)
NFLX   308.26 (-0.05%)
S&P 500   3,952.19 (+0.46%)
DOW   33,667.62 (+0.21%)
QQQ   282.85 (+0.83%)
AAPL   141.91 (+0.69%)
MSFT   246.30 (+0.79%)
META   115.50 (+1.38%)
GOOGL   94.06 (-0.93%)
AMZN   89.76 (+1.47%)
TSLA   172.33 (-0.98%)
NVDA   168.88 (+4.76%)
NIO   13.31 (+5.80%)
BABA   93.94 (+6.35%)
AMD   69.55 (-0.84%)
T   19.14 (-0.83%)
MU   55.18 (+2.53%)
CGC   3.04 (-6.17%)
F   13.10 (+0.00%)
GE   83.22 (-2.09%)
DIS   92.45 (+0.33%)
AMC   6.13 (+1.32%)
PYPL   74.15 (-0.36%)
PFE   51.72 (+2.95%)
NFLX   308.26 (-0.05%)
S&P 500   3,952.19 (+0.46%)
DOW   33,667.62 (+0.21%)
QQQ   282.85 (+0.83%)
AAPL   141.91 (+0.69%)
MSFT   246.30 (+0.79%)
META   115.50 (+1.38%)
GOOGL   94.06 (-0.93%)
AMZN   89.76 (+1.47%)
TSLA   172.33 (-0.98%)
NVDA   168.88 (+4.76%)
NIO   13.31 (+5.80%)
BABA   93.94 (+6.35%)
AMD   69.55 (-0.84%)
T   19.14 (-0.83%)
MU   55.18 (+2.53%)
CGC   3.04 (-6.17%)
F   13.10 (+0.00%)
GE   83.22 (-2.09%)
DIS   92.45 (+0.33%)
AMC   6.13 (+1.32%)
PYPL   74.15 (-0.36%)
PFE   51.72 (+2.95%)
NFLX   308.26 (-0.05%)
S&P 500   3,952.19 (+0.46%)
DOW   33,667.62 (+0.21%)
QQQ   282.85 (+0.83%)
AAPL   141.91 (+0.69%)
MSFT   246.30 (+0.79%)
META   115.50 (+1.38%)
GOOGL   94.06 (-0.93%)
AMZN   89.76 (+1.47%)
TSLA   172.33 (-0.98%)
NVDA   168.88 (+4.76%)
NIO   13.31 (+5.80%)
BABA   93.94 (+6.35%)
AMD   69.55 (-0.84%)
T   19.14 (-0.83%)
MU   55.18 (+2.53%)
CGC   3.04 (-6.17%)
F   13.10 (+0.00%)
GE   83.22 (-2.09%)
DIS   92.45 (+0.33%)
AMC   6.13 (+1.32%)
PYPL   74.15 (-0.36%)
PFE   51.72 (+2.95%)
NFLX   308.26 (-0.05%)
NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

$0.23
0.00 (-1.63%)
(As of 12/8/2022 02:22 PM ET)
Add
Compare
Today's Range
$0.23
$0.26
50-Day Range
$0.19
$12.49
52-Week Range
$0.19
$13.85
Volume
305,253 shs
Average Volume
14.01 million shs
Market Capitalization
$13.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Tricida MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7,033.9% Upside
$17.00 Price Target
Short Interest
Bearish
46.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$13.74 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.88) to ($1.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

600th out of 1,027 stocks

Pharmaceutical Preparations Industry

280th out of 503 stocks

TCDA stock logo

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

Tricida Announces Third Quarter 2022 Financial Results
Tricida Provides Strategic Update
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
Why Tricida Stock Is Tanking Today
Why Is Tricida (TCDA) Stock Down 90% Today?
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Tricida announces $125M debt facility - Seeking Alpha
Tricida Whale Trades Spotted
6TCDA : Tricida Whale Trades Spotted
See More Headlines
Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings
11/14/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+7,143.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-176,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
35,851,000
Market Cap
$13.07 million
Optionable
Not Optionable
Beta
0.08

Key Executives

  • Dr. Gerrit Klaerner Ph.D. (Age 50)
    Founder, Pres, CEO & Exec. Director
    Comp: $992.55k
  • Mr. Geoffrey M. Parker (Age 57)
    COO, CFO & Exec. VP
    Comp: $656.28k
  • Mr. Robert L. McKague J.D.
    Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
  • Dr. Dawn Parsell Ph.D. (Age 60)
    Exec. VP of Clinical Devel.
    Comp: $649.17k
  • Ms. Annie Yoshiyama (Age 39)
    VP of Fin. & Chief Accounting Officer
  • Jackie Cossmon
    VP of Investor Relations & Communications
  • Mr. Edward J. Hejlek Esq. (Age 66)
    J.D., Exec. VP of Intellectual Property













TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View TCDA analyst ratings
or view top-rated stocks.

What is Tricida's stock price forecast for 2023?

5 equities research analysts have issued 12-month price objectives for Tricida's stock. Their TCDA share price forecasts range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 7,079.1% from the stock's current price.
View analysts price targets for TCDA
or view top-rated stocks among Wall Street analysts.

How have TCDA shares performed in 2022?

Tricida's stock was trading at $9.56 at the beginning of 2022. Since then, TCDA stock has decreased by 97.5% and is now trading at $0.2368.
View the best growth stocks for 2022 here
.

When is Tricida's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our TCDA earnings forecast
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.10.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by many different institutional and retail investors. Top institutional shareholders include VR Adviser LLC (16.26%), BlackRock Inc. (6.64%), Commodore Capital LP (3.55%), Vanguard Group Inc. (2.99%), Citadel Advisors LLC (0.00%) and Point72 Asset Management L.P. (0.00%). Insiders that own company stock include Brian M Isern, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Orbimed Advisors Llc, Robert J Alpern, Robert Mckague, Sandra I Coufal, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends
.

How do I buy shares of Tricida?

Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $0.24.

How much money does Tricida make?

Tricida (NASDAQ:TCDA) has a market capitalization of $13.18 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 12/8/2022 by MarketBeat.com Staff